Outset Medical’s General Counsel John Brottem will depart his role effective September 11, 2026, to pursue other professional opportunities. For investors, the company has provided a defined transition date and said the departure is not connected to any dispute or disagreement with Outset Medical or its management.

Key Highlights

  • John Brottem informed Outset Medical of his departure decision on August 27, 2026.
  • Outset Medical said the departure is not related to a dispute or disagreement with management.
  • Brottem’s departure from Outset Medical takes effect September 11, 2026.
  • He is leaving both his general counsel position and his role with the company.

Departure Effective Date

Brottem’s departure from Outset Medical is scheduled to take effect on September 11, 2026. The date applies to both his position as general counsel and his role with the company, making the announcement broader than a change limited to one title.

The company’s disclosure places the effective date after Brottem’s notification on August 27. It does not provide additional timing details beyond the stated September 11 departure date.

Notification to Outset Medical

Brottem notified Outset Medical of his decision on August 27. That notification established the company’s understanding that he intended to leave and identified September 11, 2026, as the effective date. It records the notification date, the planned exit date, and the positions covered by the departure.

Reason for the Exit

The stated reason for Brottem’s departure is his pursuit of other professional opportunities.

This explanation frames the decision as a move toward opportunities outside the information provided about Outset Medical. No additional career plans or transition arrangements are included in the company’s described disclosure.

No Dispute or Disagreement

Outset Medical described Brottem’s departure as unrelated to any dispute or disagreement involving the company or its management. That statement directly addresses whether the exit was connected to a conflict with the organization or its leadership. Instead, the company’s stated characterization separates the departure from those circumstances.

Roles Covered by the Departure

Brottem is leaving his position as general counsel as well as his role with Outset Medical. The wording indicates that the effective September 11 departure concerns both his legal Leadership position and his broader relationship with the company. It also does not describe how the company plans to handle the functions associated with his departure.

Company Report and Signature

Renee Gaeta, Outset Medical’s chief financial officer, signed the company’s report on August 28, 2026. Her signature appears in the company reporting associated with the departure disclosure described in the article.

The report follows Brottem’s August 27 notification by one day and precedes the September 11 effective date. Beyond identifying Gaeta’s role and signature date, the article provides no further information about the report’s contents or filing process.

Peers Moving on This News

  • RetinalGenix Technologies Inc (OTC: RTGN) little changed
  • Neuraxis, Inc. (AMEX: NRXS) little changed
  • Odysight.ai Inc. (NASDAQ: ODYS) up 1.9%